Search results

For me baseline/background fatigue (or low energy) is much more of a disabling factor than fatiguability. For example, I don’t have the issue of raising my hands above my head as being a problem. Maybe we are all different or have different diseases under a syndrome umbrella. Maybe all this...

There are lots of threads on Daratumumab and cyclophosphamide—both pioneered by oncologist Fluge’s group. And there are other cancer treatments now being used for autoimmune diseases (e.g. CAR T and Tecli, etc.). Possible that treatments could come from JAK drugs or from whatever Ron Davis and...

Treatments are coming from/will come from oncology.

"Huge congratulations to our former Chair and President Clare Gerada on becoming a Crossbench Peer in the House of Lords. A lifelong College member and now a Baroness – but first and foremost a grassroots GP who continues to deliver exceptional care to your patients and to fight for the...

Yeah, I’m a fan. I think he is one of the best ME/CFS theoretical people and he is always pretty transparent that he could be wrong.

Also Rob Phair (not sure if you want to call him part of Ron Davis’ larger group because he is not at Stanford).

Porzingis with POTS—might be paywalled https://www.nytimes.com/athletic/6738610/2025/10/22/kristaps-porzingis-illness-explained-nba/?source=athletic_user_shared_article_copylink&smid=url-share-ta Also here...

It’s not that bad

Wow—I thought this was a breakthrough paper.

Looks like the final version was published—hard to link to directly because X just put this new thing where it’s hard to copy links.

I just posted this lupus preprint, which includes co-authors from UCL rheumatology @Jonathan Edwards which mentions (I think) that the spleen is a more important factor than bone marrow in Lupus. Post in thread 'Long-lived plasma cell (LLPC) theory - Similarities between CFS and Lupus?'...

https://www.biorxiv.org/content/10.1101/2025.10.20.683393v1 Autoantibody origins in lupus and in relapse post CAR-T therapy Abstract Anti-CD19 chimeric antigen receptor (CAR)-T therapy induces profound remissions in lupus by depleting B cells, challenging the longstanding view that...

Took like a year and a half from submission to publication.

Ugh

On science, AI influencers, and intellectual honesty. Scientist turned “AI influencer” @DeryaTR_, who has taken at least some funding from OpenAI, has repeatedly gone after me, often with intellectual dishonesty. It’s a good case study. Derya knows perfectly well, as a scientist, for example...

I wanted to see if the response timeline for tecli (BCMA) was similar to that of the CD-38 drugs like Daratumumab (~2 months).

Tecli basically kills plasma cells by a different mechanism without CD38 involvement—this is my understanding.

Paper—doesn’t indicate how long from first injection to first clinical response/improvement.

Abstract BACKGROUND Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) in a phase 2b trial when added to standard therapy. METHODS We conducted a...